OS Therapies announces osteosarcoma Scientific and Medical Advisory Board

OS Therapies highlights its Scientific and Medical Advisory Board, comprised of experts in osteosarcoma from six institutions in the United States. The following physicians have agreed to serve on the OS Therapies SMAB: Nabil M. Ahmed, MD – Texas Children’s Hospital; Peter M. Anderson, MD – Cleveland Clinic; Doug S. Hawkins, MD – Seattle Children’s Hospital; Meenakshi Hedge, MD – Texas Children’s Hospital; Alejandro Sweet-Cordero, MD – University of California, San Francisco; Brenda Weigel, MD – Masonic Cancer Center, University of Minnesota; Felasfa M. Wodajo, MD – Inova Fairfax Hospital, Virginia. The SMAB will assist the Company in engaging with the US Food & Drug Administration regarding the safety and efficacy of its lead immunotherapy product candidate, OST-HER2, for the treatment of osteosarcoma. This includes evaluating how OST-HER2 compares with the current standard of care in osteosarcoma, particularly in relation to a potential Biologics License Authorization following the completion of the ongoing clinical trial for OST-HER2.